Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

Stifel on Neurocrine Bio. (NBIX): 'Really Nice Ingrezza Quarter, Guidance Starting to Look Potentially Conservative'

May 4, 2022 10:25 AM EDT

Stifel analyst Paul Matteis reiterated a Buy rating and $136.00 price target on Neurocrine Bio. (NASDAQ: NBIX).

The analyst comments "We are reiterating our Buy rating on NBIX on a strong quarter for Ingrezza ($303MM) which beat our estimate and consensus by ~$23MM and... More

Raymond James on Neurocrine Bio. (NBIX): 'Solid Beat for Ingrezza; Well Positioned Moving Forward'

May 4, 2022 10:24 AM EDT

Raymond James analyst Danielle Brill reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX).

The analyst comments "Ingrezza 1Q revenues solidly beat expectations, and FY22 guidance was rea"irmed. Lighter seasonal payer headwinds and enhanced compliance helped contribute to the strong Ingrezza revenue... More

Neurocrine Biosciences (NBIX) Misses Q1 EPS by 5c

May 4, 2022 7:36 AM EDT

Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.30, $0.05 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $310.6 million versus the consensus estimate of $304.19 million.

Reiterated 2022 INGREZZA Sales and Operating Expense... More